Analysis of the Effect of Intravitreal Bevacizumab Injection on Diabetic Macular Edema after Cataract Surgery

Ophthalmology

Volumn 116, Issue 6, 2009, Pages 1151-1157

  Takamura, Yoshihiro ^a   Kubo, Eri ^a   Akagi, Yoshio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LENS IMPLANT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PHACOEMULSIFICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS; LENS IMPLANTATION, INTRAOCULAR; MACULAR EDEMA; MALE; PHACOEMULSIFICATION; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 67349105083     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.01.014     Document Type: Article

References (43)

1. Moss S.E., Klein R., and Klein B.E. The incidence of visual loss in a diabetic population. Ophthalmology 95 (1988) 1340-1348
2. Joussen A.M., Smyth N., and Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 39 (2007) 1-12
3. Nelson M.L., and Martidis A. Managing cystoid macula edema after cataract surgery. Curr Opin Ophthalmol 14 (2003) 39-43
4. Chew E.Y., Benson W.E., Remaley N.A., et al., Early Treatment Diabetic Retinopathy Study Research Group. Results after lens extraction in patients with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report number 25. Arch Ophthalmol 117 (1999) 1600-1606
5. Kim S.J., Equi R., and Bressler N.M. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 114 (2007) 881-889
6. Toth C.A., Narayan D.G., Boppart S.A., et al. A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy. Arch Ophthalmol 115 (1997) 1425-1428
7. Hee M.R., Puliafito C.A., Duker J.S., et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 105 (1998) 360-370
8. Ozdek S.C., Erdinc M.A., Gurelik G., et al. Optical coherence tomographic assessment of diabetic macular edema: comparison with fluorescein angiographic and clinical findings. Ophthalmologica 219 (2005) 86-92
9. Sugimoto M., Sasoh M., Ido M., et al. Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica 219 (2005) 379-385
10. Schaudig U.H., Glaefke C., Scholz F., and Richard G. Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema. Ophthalmic Surg Lasers 31 (2000) 182-186
11. Pollack A., Leiba H., Bukelman A., et al. The course of diabetic retinopathy following cataract surgery in eyes previously treated by laser photocoagulation. Br J Ophthalmol 76 (1992) 228-231
12. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
13. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125 (2007) 469-480
14. Flach A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96 (1998) 557-634
15. Conway M.D., Canakis C., Livir-Rallatos C., and Peyman G.A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29 (2003) 27-33
16. Koutsandrea C., Moschos M.M., Brouzas D., et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina 27 (2007) 159-164
17. Harbour J.W., Smiddy W.E., Rubsamen P.E., et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 120 (1995) 302-307
18. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
19. Funatsu H., Yamashita H., Nakamura S., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macula edema. Ophthalmology 113 (2006) 294-301
20. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
21. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
22. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
23. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
24. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114 (2007) 743-750
25. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
26. Chylack Jr. L.T., Wolfe J.K., Singer D.M., et al., Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol 111 (1993) 831-836
27. Lee C.M., Olk R.J., and Akduman L. Combined modified grid and panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy. Opthalmic Surg Lasers 31 (2000) 292-300
28. Cunha-Vaz J.G. Studies on the pathophysiology of diabetic retinopathy: the blood-retinal barrier in diabetes. Diabetes 32 suppl (1983) 20-27
29. Stern A.L., Taylor D.M., Dalburg L.A., and Cosentino R.T. Pseudophakic cystoid maculopathy: a study of 50 cases. Ophthalmology 88 (1981) 942-946
30. Qaum T., Xu Q., Joussen A.M., et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42 (2001) 2408-2413
31. Patel J.I., Hykin P.G., and Cree I.A. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol 90 (2006) 697-701
32. Mason III J.O., Albert Jr. M.A., and Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26 (2006) 356-357
33. Arevalo J.F., Garcia-Amaris R.A., Roca J.A., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 33 (2007) 2098-2105
34. Spitzer M.S., Ziemssen F., Yoeruek E., et al. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 34 (2008) 70-75
35. Somaiya M.D., Burns J.D., Mintz R., et al. Factors affecting visual outcomes after small-incision phacoemulsification in diabetic patients. J Cataract Refract Surg 28 (2002) 1364-1371
36. Kang S.W., Park C.Y., and Ham D.I. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macula edema. Am J Ophthalmol 137 (2004) 313-322
37. Jonas J.B., Kreissig I., Söfker A., and Degenring R.F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121 (2003) 57-61
38. Sutter F.K., Simpson J.M., and Gillies M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111 (2004) 2044-2049
39. Massin P., Audren F., Haouchine B., et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111 (2004) 218-224
40. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
41. Shimura M., Nakazawa T., Yasuda K., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145 (2008) 854-861
42. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1459
43. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 114 (2007) 1190-1196